Cvrx, Inc

barostim.com

What Do They Do?

Sells Barostim, an implantable electrical-stimulation device for improving heart-failure symptoms, to hospitals treating patients with heart failure.

How Do They Make Money?

Hospitals and other customers pay for Barostim’s implantable components when the products are delivered; customer payment terms are generally 30 to 90 days.

FY2025 revenue

Who Are Their Customers?

Hospitals buy Barostim directly in the U.S. and Germany; sales in Austria, Spain, and other European countries go through distributors.

Do Revenues Turn Into Profits?

No. It lost $53.3M in FY2025.

Operating income, FY2025

−90% of revenue

▼ −14% (Loss) vs FY2024 (−$59.5M, −116%)

Net income, FY2025

−94% of revenue

▼ −11% (Loss) vs FY2024 (−$60M, −117%)

Free cash flow, FY2025

−72% of revenue

▲ +1% (Loss) vs FY2024 (−$40.5M, −79%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +16%; vs $13.6M in Q2 FY2025
Net income: ▼ −5% (Loss); vs −$14.7M in Q2 FY2025

Aug 6, 2026 CVRx issued updated 2026 and third-quarter revenue outlook CVRx expects full-year 2026 revenue of $58.0 million to $60.0 million and third-quarter revenue of $13.5 million to $14.5 million.
Jun 9, 2026 CFO Jared Oasheim gave notice of his intention to resign He will remain CFO until a successor begins; the company is searching for a successor.

Growing. Revenue grew 4.3x in 4 years, from $13M in FY2021 to $56.7M in FY2025, about 44% a year.

Comments